Fig. 2.

Changes in BMD after the start of DMAb treatment as determined by radial DXA (∆BMD = [radial DXA value for each week] − [radial DXA value at the start of treatment]). In the PO group, the radial DXA value increased with the number of doses (over time). Treatment with DMAb was also associated with increases in the radial DXA value in the RA and RA + GC groups. However, the efficacy of DMAb in increasing radial DXA values was slower in onset than in the PO group. At week 52 of DMAb treatment, statistically significant differences were found in BMD between the PO and RA or RA + GC groups (p < 0.05). Treatment with bisphosphonate showed no increase in the radial DXA value, and the effect of bisphosphonate was statistically significantly inferior to that of DMAb (p < 0.01). Data are expressed as mean ± standard error. ∆BMD change in bone mineral density, BMD bone mineral density, DMAb denosumab, PO patients with postmenopausal osteoporosis, RA osteoporosis patients with rheumatoid arthritis, RA + GC osteoporosis patients with rheumatoid arthritis taking glucocorticoids, radial DXA radial dual-energy X-ray absorptiometry